1-5 of 5
Meg Elias, RN, BSN
Close
Sort by
Journal Articles

Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, David B. Miklos, MD PhD, Eric D. Jacobsen, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John M Timmerman, MD, Patrick M. Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, Meg Elias, RN,BSN, Jeffrey S. Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 578.
https://doi.org/10.1182/blood.V130.Suppl_1.578.578
Published: 2017
Journal Articles

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, MD, Sattva S. Neelapu, MD, Nancy L. Bartlett, MD, Lazaros J. Lekakis, MD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John M Timmerman, MD, Patrick M. Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Marika Sherman, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, Meg Elias, RN,BSN, Jeffrey S. Wiezorek, MD MS, William Y. Go, MD PhD, David B. Miklos, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1547.
https://doi.org/10.1182/blood.V130.Suppl_1.1547.1547
Published: 2017
Journal Articles

A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Caron A. Jacobson, MD, Jason R. Westin, MD, Julio C. Chavez, MD, Armin Ghobadi, MD, Alex F Herrera, MD, Ann S. LaCasce, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Yizhou Jiang, PhD, Jeff S. Aycock, BA, Meg Elias, RN,BSN, Jeff Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2016) 128 (22): 998.
https://doi.org/10.1182/blood.V128.22.998.998
Published: 2016
Journal Articles

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros Lekakis, MD, David Miklos, MD PhD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John Timmerman, MD, Patrick J. Stiff, Jonathan Friedberg, MD, Ian Flinn, Andre Goy, MD, Mitchell Smith, Abhinav Deol, MD, Umar Farooq, MD, Peter McSweeney, MD, Javier Munoz, MD, Irit Avivi, MD, Januario E. Castro, MD, Jason R. Westin, MD MS, Julio C. Chavez, MD, Armin Ghobadi, MD, Krishna V. Komanduri, MD, Ronald Levy, MD, Eric D. Jacobsen, Patrick Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, BA, Meg Elias, RN, BSN, Jeff Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2016) 128 (22): LBA-6.
https://doi.org/10.1182/blood.V128.22.LBA-6.LBA-6
Published: 2016
Journal Articles

Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

John M. Rossi, MS, Sattva S. Neelapu, MD, William Y. Go, MD PhD, Yueh-wei Shen, MS, Marika Sherman, MS, Frederick L. Locke, MD, Nancy L Bartlett, MD, Tanya Siddiqi, MD, Lynn Navale, MS, Meg Elias, RN,BSN, Jeff Wiezorek, MD MS, Adrian Bot, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2730.
https://doi.org/10.1182/blood.V126.23.2730.2730
Published: 2015